Video: Further Considerations of the ORAL Surveillance Study Further Considerations of ORAL Surveillance Study - this week there are new analyses and sub-analyses that further explain findings and who this data applies to. #EULAR2022 https://t.co/a2XKthtMbs https://t.co/kYNS1AesHT

• https://bit.ly/3Ne2K9u

Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb

Study of 2.9k offspring exposed to adalimumab, infliximab, golimumab during pregnancy, as compared to etanercept and certolizumab showed an adjusted hazard ratio for serious infections of 1.20 (CI 0.54, 2.64). @RheumNow #EULAR2022 ABST#OP0130

GM-CSF increased in patients with active ankylosing spondylitis, correlates with disease activity, not duration. TNFi does not affect GM-CSF levels. Could explain efficacy of JAKinibs and response for residual inflammation during TNF blockade. @RheumNow #EULAR2022 ABST#OP0107

Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis). @RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW